Results 31 to 40 of about 34,307 (290)
Identification of minimal sequence for HIV-1 fusion inhibitors [PDF]
Bioorganic & Medicinal Chemistry, 2008 Emergence of multi-drug resistant HIV-1 is a serious problem for AIDS treatment. Recently, the virus-cell membrane fusion process has been identified as a promising target for the development of novel drugs against these resistant variants. In this study, we identified a 29-residue peptide fusion inhibitor, SC29EK, which shows activity comparable to ...
Nishikawa, Hiroki +12 more
openaire +2 more sources
Acta Médica Portuguesa, 2008 Human immunodeficiency virus (HIV) infection of host cells begins with binding of viral envelope (Env) surface (SU) glycoprotein to specific receptors present at plasma cell membrane.
J M Azevedo-Pereira, Q Santos-Costa
doaj +1 more source
Intercellular adhesion molecule 1 promotes HIV-1 attachment but not fusion to target cells. [PDF]
PLoS ONE, 2012 Incorporation of intercellular adhesion molecule 1 (ICAM-1) into HIV-1 particles is known to markedly enhance the virus binding and infection of cells expressing lymphocyte function-associated antigen-1 (LFA-1). At the same time, ICAM-1 has been reported
Naoyuki Kondo, Gregory B Melikyan
doaj +1 more source
Anti-HIV therapy: pipeline approaches and future directions
, 2011 Human immunodeficiency virus (HIV), with about 30 million deaths and double infections (in developing countries), is an open challenge today for global scientists.
Lavkush Dwivedi, Mansi Shrivastava
core +1 more source
HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics
Journal of the Formosan Medical Association, 2010 Human immunodeficiency virus (HIV)-1 infection is initiated by the binding of gp120 envelope glyco-protein to its cell receptor (CD4) and a coreceptor (CXCR4 or CCR5), followed by a series of conformational changes in the gp41 transmembrane subunit ...
Chungen Pan, Shuwen Liu, Shibo Jiang
doaj +1 more source
The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance. [PDF]
PLoS ONE, 2017 Most mechanistic studies on human immunodeficiency virus (HIV) peptide fusion inhibitors have focused on the interactions between fusion inhibitors and viral envelope proteins.
Ping Cao +3 more
doaj +1 more source
Amphipathic Properties of HIV-1 gp41 Fusion Inhibitors [PDF]
Current Topics in Medicinal Chemistry, 2011 Small molecule inhibition of HIV fusion has been an elusive goal, despite years of effort by both pharmaceutical and academic laboratories. In this review, we will discuss the amphipathic properties of both peptide and small molecule inhibitors of gp41-mediated fusion.
Miriam, Gochin, Guangyan, Zhou
openaire +2 more sources
FEBS Letters, EarlyView.Plasma membranes contain dynamic nanoscale domains that organize lipids and receptors. Because viruses operate at similar scales, this architecture shapes early infection steps, including attachment, receptor engagement, and entry. Using influenza A virus and HIV‐1 as examples, we highlight how receptor nanoclusters, multivalent glycan interactions ...
Jan Schlegel, Christian Sieben
wiley +1 more source
Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. [PDF]
PLoS ONE, 2013 The HIV-1 envelope glycoprotein (Env) gp41 plays a crucial role in the viral fusion process. The peptides derived from the C-terminal heptad repeat (CHR) of gp41 are potent HIV fusion inhibitors. However, the activity of these anti-HIV-1 peptides in vivo
Lijun Chao +8 more
doaj +1 more source
FEBS Open Bio, EarlyView.The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley +1 more source